Free press releases distribution network?

Agency / Source: RNCOS E-Services (P) Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Huge Opportunities for Indian Generics Drug Sector Ramping Up in the U.S Finds RNCOS - Backed by factors like patent expiries of blockbuster drugs and strong demand, the Indian generics drug market will grow at a CAGR of 17% between FY 2011 and FY 2013
Huge Opportunities for Indian Generics Drug Sector Ramping Up in the U.S Finds RNCOS

 

PRZOOM - /newswire/ - Noida, Uttar Pradesh, India, 2011/08/01 - Backed by factors like patent expiries of blockbuster drugs and strong demand, the Indian generics drug market will grow at a CAGR of 17% between FY 2011 and FY 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

According to our latest report,“Booming Generics Drug Market in India”, the Indian generics drug market has been growing at a rapid pace over the past few years. Despite the recession, the market continued to perform well and reached an estimated mark of US$ 17 Billion in FY 2010. Factors including patent expiries, increasing awareness & access, and private investment are the prominent growth drivers that will lead Indian generics market to grow at a CAGR of around 17% between FY 2011 and FY 2013.

We have found that US is the key destination for expanding Indian drug manufacturers, as a large number of drugs are scheduled to go off patent. In 2012, drugs worth US$ 35.4 Billion are likely to lose their patents in the US. This creates a huge opportunity for Indian companies, who already have enjoyed 10.5% share in the US generics market. In this regard, our report analyzes the opportunity for Indian drug manufacturers in key regions of the world.

The report,“Booming Generics Drug Market in India”, addresses all the pertinent issues related to generics drug market in India and covers information on the market development. The report also investigates the current trends and discusses their impact on the market performance. Regulatory environment has also been analyzed so that client may acquaint themselves with the government role in market development.

The report is an outcome of prudent research and in-depth analysis of several segments, such as API and formulation drugs of Indian generic and pharmaceutical market. The forecast is done after comprehending the current market scenario, past trends and ongoing developments in the industry. A brief description, strength-weakness analysis and recent developments of key market players have also been included in order to analyze private sector participation.

Report/IM256

About RNCOS
RNCOS (rncos.com) specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: RNCOS E-Services (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Huge Opportunities for Indian Generics Drug Sector Ramping Up in the U.S Finds RNCOS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Shushmul Maheshwari - RNCOS.com 
+91 12 04224700 press[.]rncos.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any RNCOS E-Services (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From RNCOS E-Services (P) Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Intrinsic Executive Search Ltd

Visit  1Click Games







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today